Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
J Neurochem. 2021 Aug;158(3):603-620. doi: 10.1111/jnc.15314. Epub 2021 Mar 10.
DREADDs (Designer Receptors Exclusively Activated by a Designer Drug) are designer G protein-coupled receptors (GPCRs) that are widely used in the neuroscience field to modulate neuronal activity. In this review, we will focus on DREADD studies carried out with genetically engineered mice aimed at elucidating signaling pathways important for maintaining proper glucose and energy homeostasis. The availability of muscarinic receptor-based DREADDs endowed with selectivity for one of the four major classes of heterotrimeric G proteins (G , G , G , and G ) has been instrumental in dissecting the physiological and pathophysiological roles of distinct G protein signaling pathways in metabolically important cell types. The novel insights gained from this work should inform the development of novel classes of drugs useful for the treatment of several metabolic disorders including type 2 diabetes and obesity.
DREADDs(受 Designer Drug 专门激活的 Designer Receptors)是设计的 G 蛋白偶联受体(GPCRs),广泛用于神经科学领域以调节神经元活动。在这篇综述中,我们将重点介绍使用基因工程小鼠进行的 DREADD 研究,旨在阐明维持适当葡萄糖和能量稳态的重要信号通路。基于毒蕈碱受体的 DREADD 的可用性,其对四种主要异三聚体 G 蛋白(G 、G 、G 和 G )中的一种具有选择性,这对于解析不同 G 蛋白信号通路在代谢重要细胞类型中的生理和病理生理作用至关重要。从这项工作中获得的新见解应该为治疗包括 2 型糖尿病和肥胖症在内的几种代谢疾病的新型药物的开发提供信息。